Spectrum Pharmaceuticals Class Action Lawsuit SPPI | Deadline February 3, 2023

Announcement! The chance to join the SPPI Lawsuit is open to all investors who purchased or otherwise acquired Spectrum Pharmaceuticals Inc. (Spectrum Pharmaceuticals Class Action Lawsuit) ordinary shares between December 6, 2021, and September 22, 2022.

CLICK HERE FOR MORE DETAILS ABOUT THE SPPI CLASS ACTION LAWSUIT

The defendants allegedly made the following claims throughout the Class Period and/or omitted to disclose them, per the SPPI lawsuit:

According to the filed complaint, the defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although Defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.

If you suffered a loss in SPPI Lawsuit, you have until February 3, 2023, to request that the Court appoint you as the lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.